Skip to main content
    D

    Denali Therapeutics Inc (DNLI)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $20.07
    +0.35 (+1.77%)

    Market Cap: $3.16B

    Last updated: Nov 06, 2026 at 4:20 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    56%(20/36)
    Avg Surprise
    +14.79%
    Streak
    6 Q

    Upcoming Estimates

    Period ending Dec 31, 2026
    EPS Consensus$-0.69
    Range$-1.21 - $1.32
    17 analysts
    Revenue Consensus
    $23M
    Range$-5712450 - $235M
    19 analysts
    Last 12 of 38 reported quarters and 1 upcoming estimate
    PeriodReportedEst.RangeSurpriseB/MAnalystsRevisionsYoY
    Dec 26EST
    		-$-0.69$-1.21 - $1.32--17--
    Sep 26
    Reported Nov 3
    		$-0.64$-0.69$-0.88 - $0.38+7.25%Beat17
    2
    0
    30d
    		+13.5%
    Jun 26
    Reported Aug 6
    		$-0.68$-0.72$-0.89 - $0.36+5.56%Beat15
    1
    0
    30d
    		+5.6%
    Mar 26
    Reported May 7
    		$-0.69$-0.71$-0.80 - $-0.54+2.82%Beat12
    4
    1
    30d
    		+11.5%
    Dec 25
    Reported Feb 26
    		$-0.73$-0.75$-0.93 - $-0.62+2.67%Beat15
    1
    0
    30d
    		-9.0%
    Sep 25
    Reported Nov 6
    		$-0.74$-0.76$-0.88 - $-0.68+2.63%Beat15
    6
    2
    30d
    		-17.5%
    Jun 25
    Reported Aug 11
    		$-0.72$-0.74$-0.93 - $-0.43+2.70%Beat14
    1
    0
    30d
    		-22.0%
    Mar 25
    Reported May 6
    		$-0.78$-0.70$-0.77 - $-0.57-11.43%Miss12
    2
    1
    30d
    		+0.0%
    Dec 24
    Reported Feb 27
    		$-0.67$-0.85$-1.13 - $-0.41+20.79%Beat12
    1
    2
    30d
    		+22.1%
    Sep 24
    Reported Nov 6
    		$-0.63$-0.63$-0.74 - $-0.45+0.00%Beat16
    1
    0
    30d
    		+12.5%
    Jun 24
    Reported Aug 1
    		$-0.59$-0.69$-0.85 - $-0.43+14.49%Beat16
    1
    0
    30d
    		-145.4%
    Mar 24
    Reported May 7
    		$-0.78$-0.66$-0.86 - $-0.53-18.18%Miss15
    2
    0
    30d
    		+2.5%
    Dec 23
    Reported Feb 27
    		$-0.86$-0.80$-0.96 - $-0.71-7.50%Miss15
    No revisions (30d)
    		-14.7%

    Key Metrics

    Valuation
    P/E Ratio-7.32EV/EBITDAN/A
    Price/FCF-8.40xFCF Yield-11.90%
    Profitability
    Profit Margin0.00%Operating Margin-709.00%
    ROE-33.90%ROICN/A
    Financial Health
    Debt/Equity0.00xInterest CoverageN/A
    Current Ratio6.21xQuick Ratio5.94x
    Trading Statistics
    Beta1.08Avg Volume1.83M
    52-Week High$27.3052-Week Low$15.18

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$19.45
    SMA 20$18.92
    SMA 50$20.16
    SMA 200$21.26
    EMA 10$19.55
    EMA 20$19.41
    EMA 50$20.20
    EMA 200$20.54

    MACD

    Line: -0.04Signal: -0.32Hist: 0.28

    ADX

    ADX: 23.9+DI: 32.1-DI: 17.6

    Aroon & PSAR

    Aroon Up92.0
    Aroon Down44.0
    PSAR$18.42

    Bollinger Bands

    Upper Band$20.47
    Lower Band$17.37
    %B Position1641%(Upper)
    Band Width0.87

    RSI (14-Day)

    Neutral
    54.1

    Momentum Oscillators

    Stoch %K58.0
    Stoch %D67.6
    Williams %R-49.9
    ROC (10d)9.0%
    Momentum1.66
    CCI (20d)129.1
    MFI (14d)66.2

    Volatility Measures

    ATR (14d)$0.93(4.7%)
    StdDev (20d)0.78
    Hist Vol51.8%(High)

    Volume Flow

    VWAP$20.07
    OBV-2.5M
    AD Line-15.5M
    CMF (20d)0.010

    Volume Metrics

    Avg Vol (20d)1.8M
    Vol Ratio0.9x
    VWMA (20d)$19.06

    Pivot Points

    R3$22.08
    R2$21.58
    R1$20.65
    Pivot Point$20.15
    S1$19.22
    S2$18.72
    S3$17.79

    Advanced Oscillators

    TSI-1.68
    Ultimate Osc47.5
    KST-25.87

    Financial Data

    QuarterSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total Revenue$17.78M$3.60M$0$0$0$0$0$0$0$0$0$-305,043,000
    Cost of Revenue$192,000$93,000$0$2.87M$0$0$0N/A$0$0$0$2.18M
    Gross Profit$17.59M$3.51M$0$-2,866,000$0$0$0N/A$0$0$0$-307,220,000
    Operating Expenses$144.34M$134.05M$137.36M$137.37M$137.43M$134.96M$145.58M$129.85M$123.19M$116.59M$117.72M$132.57M
    R&D$106.10M$97.02M$103.85M$97.91M$101.95M$102.70M$116.23M$99.79M$98.24M$91.40M$107.02M$107.80M
    SG&A$37.48M$36.28M$33.51M$39.46M$35.48M$32.27M$29.35M$30.06M$24.95M$25.19M$25.24M$24.77M
    Operating Income$-126,751,000$-130,541,000$-137,357,000$-137,365,000$-137,434,000$-134,963,000$-145,580,000$-129,846,000$-123,187,000$-116,593,000$-117,715,000$-132,572,000
    Interest Income$2.88M$2.99M$8.91M$8.92M$10.53M$10.84M$12.61M$15.16M$15.99M$17.57M$15.91M$13.13M
    Interest Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Income Before Tax$70.13M$-127,553,000$-128,447,000$-128,447,000$-126,902,000$-124,119,000$-132,970,000$-114,685,000$-107,192,000$-99,026,000$-101,802,000$-119,443,000
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Net Income$70.13M$-127,553,000$-128,447,000$-128,549,000$-126,902,000$-124,119,000$-132,970,000$-114,753,000$-107,192,000$-99,026,000$-101,802,000$-119,473,000
    EBITDA$71.74M$-126,057,000$-133,596,000$-133,583,000$-133,572,000$-131,007,000$-142,368,000$-127,227,000$-120,918,000$-114,651,000$-115,553,000$-130,395,000
    EBIT$67.25M$-130,541,000$-137,357,000$-137,365,000$-137,434,000$-134,963,000$-145,580,000$-129,846,000$-123,187,000$-116,593,000$-117,715,000$-132,572,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about DNLI

    News

    Denali Therapeutics (DNLI) Stock Price, Chart & Analysis

    This article provides a detailed analysis of Denali Therapeutics (DNLI) stock, including its latest price, market capitalization...

    www.debelegger.nl•11/5/26•Somewhat-Bearish

    DNLI Up 7.8% Post Q3 Earnings: Should You Buy, Sell or Hold the Stock?

    Denali Therapeutics, Inc. (DNLI) reported better-than-expected Q3 earnings, with a narrower loss and higher revenues, driven by the strong commercial uptake of its lead drug...

    TradingView•11/5/26•Bullish

    Denali Therapeutics Inc (DNLI) Q3 2026 Earnings Call Highlights: AVLAYAH Revenue Soars Nearly ...

    Denali Therapeutics Inc. reported strong Q3 2026 earnings, with AVLAYAH net product revenue reaching $17.8 million...

    Yahoo Finance Singapore•11/4/26•Bullish

    Denali Therapeutics Reports Third Quarter 2026 Financial Results and Business Highlights

    Denali Therapeutics announced strong third-quarter 2026 financial results, with net income of $70.1 million, driven by $17.8 million in net product revenue from AVLAYAH® and a $194.0 million gain from a Priority Review...

    The Manila Times•11/4/26•Bullish

    Denali Therapeutics Q4 Results: Sales guidance $30M-$32M beats estimates

    Denali Therapeutics reported strong Q3 revenue of $17.778 million, significantly beating analyst estimates, although adjusted EPS missed expectations. The company also issued robust Q4 sales guidance of $30 million...

    scanx.trade•11/3/26•Somewhat-Bullish

    DNLI Valuation and Fair Value

    P/E
    -7.3x
    P/FCF
    -8.4x
    P/B
    4.1x
    See GNG's fair value

    DNLI Profitability: Margins, ROIC and FCF

    Operating margin
    -709.0%
    Net margin
    0.0%
    ROE
    -33.9%
    FCF margin
    -2104.5%
    FCF yield
    -11.9%

    DNLI Competitors

    CompanyTicker
    Telix Pharmaceuticals LimitedTLX
    Surgery Partners IncSGRY
    Dyne Therapeutics IncDYN
    Aveanna Healthcare Holdings IncAVAH
    Viridian Therapeutics IncVRDN
    Bausch Health Companies IncBHC
    Enliven Therapeutics Inc.ELVN
    Ideaya Biosciences IncIDYA

    Sector: Healthcare

    DNLI Analyst Ratings

    Consensus
    Buy
    Analysts
    20
    Strong Buy
    2
    Buy
    17
    Hold
    1
    Sell
    0
    Strong Sell
    0

    DNLI Bull Case vs Bear Case

    Bull case

    • DNLI beat EPS estimates in 87.5% of its last 8 reported quarters.
    • 95.0% of DNLI's analyst ratings are Buy or Strong Buy.

    Bear case

    • DNLI's quarterly revenue changed -100.0% year over year.

    DNLI Earnings: Beat Rate and Next Report

    Beat rate
    7 of 8 quarters (87.5%)
    Average surprise
    4.1%
    EPS estimate (fiscal period ending Dec 31, 2026)
    $-0.69

    DNLI Earnings Date

    DNLI reports Feb 24, 2027, after the close. The date is estimated.

    DNLI Earnings Call

    The latest DNLI earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    DNLI ETF Holders

    GNG tracks 17 ETFs that hold DNLI. The largest weights:

    1. abrdn Healthcare Investors (HQH), 2.01% of the fund
    2. State Street SPDR S&P Biotech ETF (XBI), 0.57% of the fund
    3. iShares Biotechnology ETF (IBB), 0.20% of the fund
    4. Vanguard Russell 2000 Index Fund ETF Shares (VTWO), 0.09% of the fund
    5. BlackRock Health Sciences Trust (BME), 0.08% of the fund
    Open the ETF Stock Exposure tool for DNLI

    See insider activity

    Frequently Asked Questions About DNLI

    When does DNLI report earnings?

    Denali Therapeutics Inc (DNLI) is expected to report earnings on Feb 24, 2027.

    Does DNLI pay dividends?

    Denali Therapeutics Inc (DNLI) does not currently pay a regular dividend.

    What is DNLI's market cap?

    Denali Therapeutics Inc (DNLI) has a market capitalization of $3.16B with a current stock price of $20.07.

    Related stocks

    Sector: Healthcare

    All stocks starting with D

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In